EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, the leader in precision-engineered cell mimic technologies, today announced the launch of TruCytes™ Potency, a new class of biomarker cell ...
Thepatent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, ...
Slingshot Biosciences (“Slingshot”) today announced two additions to its TruCytes™ cell mimic product line designed to accelerate cell therapy and stem cell research, development, and manufacturing ...
Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...
Announcing a new article publication for BIO Integration journal. Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor. Cell and gene ...
CAR T-cell therapy is considered a revolution in cancer treatment, offering several advantages over traditional chemotherapy. It provides precise targeting of specific cancer types, uses the patient's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results